Current topics and perspectives relating to hormone therapy for prostate cancer

International Journal of Clinical Oncology

Volumn 13, Issue 5, 2008, Pages 401-410

  Suzuki, Hiroyoshi ^a   Kamiya, Naoto ^a   Imamoto, Takashi ^a   Kawamura, Koji ^a   Yano, Masashi ^a   Takano, Makoto ^a   Utsumi, Takanobu ^a   Naya, Yukio ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antiandrogen; Hormone therapy; Hormone refractory; Intermittent androgen suppression; Prostate cancer

Indexed keywords

ANTIANDROGEN; AROMATASE; BICALUTAMIDE; CHLORMADINONE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOCETAXEL; FLUTAMIDE; GONADORELIN AGONIST; NILUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; TESTOSTERONE; TUMOR MARKER;

ADJUVANT THERAPY; ANEMIA; BODY FAT; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DNA POLYMORPHISM; DRUG WITHDRAWAL; EMOTIONAL STRESS; FATIGUE; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMPOTENCE; INTERSTITIAL PNEUMONIA; LIBIDO DISORDER; LIVER DYSFUNCTION; MONOTHERAPY; MUSCLE ATROPHY; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; NOMOGRAMS; ORCHIECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 54849440376     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0830-y     Document Type: Review

References (43)

1. T. Imamoto H. Suzuki M. Yano 2008 The role of testosterone in the pathogenesis of prostate cancer Int J Urol 15 472 480
2. C. Huggins C.V. Hodges 1941 Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293 297
3. T. Tammela 2004 Endocrine therapy of prostate cancer J Steroid Biochem Mol Biol 92 287 295
4. D.A. Loblaw S.V. Virgo R. Nam 2007 Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 1596 1605
5. P. Iversen 1999 Quality of life issues relating to endocrine treatment options Eur Urol 36 Suppl2 20 26
6. M.R. Smith M. Goode A.L. Zietman 2004 Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition J Clin Oncol 22 2546 2553
7. P. Iversen T.L.J. Tammela S. Vaage 2002 A randomised comparison of bicalutamide ("Casodex") 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostate Cancer Group Study No. 6 Eur Urol 42 204 211
8. L. Boccon-Gibbod 1998 Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Eur Urol 33 159 164
9. M. Nakabayashi R.A. Bartlett W.K. Oh 2006 Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer J Clin Oncol 24 2958 2959
10. S. Hinotsu H. Akaza M. Usami 2007 Current status of endocrine therapy for prostate cancer in Japan. Analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP Jpn J Clin Oncol 37 775 781
11. E.D. Crawford M.A. Eisenberger D.G. McLeod 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 419 424
12. L.J. Denis G.P. Murphy 1993 Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer Cancer 72 Suppl 3888 3895
13. Prostate Cancer Trialists' Collaborative Group 1995 Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients Lancet 346 265 269
14. M.A. Eisenberger B.A. Blumenstein E.D. Crawford 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 1036 1042
15. Prostate Cancer Trialists' Collaborative Group 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 355 1491 1498
16. M. Usami T. Kotake H. Akaza 1998 The effects of chlormadinone acetate or fosfestrol on the LH-RH agonist-based treatment of advanced prostate cancer Jpn J Urol Surg 11 759 772
17. H. Akaza A. Yamaguchi T. Matsuda 2004 Superior antitumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients Jpn J Clin Oncol 34 20 28
18. P.F. Schellhammer R. Sharifi N.L. Block 1997 Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized multicenter trial Urology 50 330 336
19. Arai Y, Akaza H, Deguchi T, et al. (2008) Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol
20. N. Bruchovsky P.S. Rennie A.J. Coldman 1990 Effcts of androgen withdrawal on the stem cell composition of Shionogi carcinoma Cancer Res 50 2275 2282
21. K. Akakura N. Bruchovsky S.L. Goldenberg 1993 Effects of intermittent androgen suppression on androgen-dependent tumors Apoptosis and serum prostate-specific antigen. Cancer 71 2782 2790
22. M.E. Gleave J.T. Hsieh H.C. Wu 1992 Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors Cancer Res 52 1598 1605
23. L.H. Klotz H.W. Herr M.J. Morse 1986 Intermittent endocrine therapy for advanced prostate cancer Cancer 58 2546 2550
24. S.L. Goldenberg N. Bruchovsky M.E. Gleave 1995 Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 48 800 804
25. M.S. Bhandari J. Crook M. Hussain 2005 Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 23 8212 8218
26. G.L. Shaw P. Wilson J. Cuzick 2007 International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients BJU Int 99 1056 1065
27. W.K. Kelly H.I. Scher 1993 Prostate specific antigen decline after antiandrogen withdrawal: the FLT withdrawal syndrome J Urol 149 607 609
28. H.I. Scher Z.F. Zhang D. Nanus 1996 Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer Urology 47 61 69
29. H. Suzuki T. Ueda T. Ichikawa 2003 Androgen receptor involvement in the progression of prostate cancer Endocr Relat Cancer 10 209 216
30. S. Kojima H. Suzuki K. Akakura 2004 Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy J Urol 171 679 683
31. H. Suzuki K. Okihara H. Miyake 2008 Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that has relapsed after initial maximum androgen blockade J Urol 180 921 927
32. H. Miyake I. Hara H. Eto 2005 Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer BJU Int 96 791 795
33. T. Hara J. Miyazaki H. Arai 2003 Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res 63 149 153
34. H.I. Scher G. Steineck W.K. Kelly 1995 Hormone-refractory (D3) prostate cancer: refining the concept Urology 46 142 148
35. N. Tsuchiya L. Wang H. Suzuki 2006 Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with meta-static prostate cancer J Clin Oncol 24 1982 1989
36. T. Imamoto H. Suzuki K. Akakura 2001 Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer Endocr J 48 573 578
37. M. Shimbo H. Suzuki N. Kamiya 2005 CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer Eur Urol 47 557 563
38. D.P. Petrylak C.M. Tangen M.H. Hussain 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520
39. I.F. Tannock R. deWit W.R. Berry 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512
40. O. Smaletz H.I. Scher E.J. Small 2002 Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 3972 3982
41. A.W. Partin M.W. Kattan E.N. Subong 1997 Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update JAMA 277 1445 1451
42. M.W. Kattan S.F. Shariat B. Andrews 2003 The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer J Clin Oncol 21 3573 3579
43. G. Attard A.S. Belldegrun J.S. Bono 2005 Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer BJU Int 96 1241 1246